WallStSmart

Merck & Company Inc (MRK)vsPalisade Bio Inc (PALI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 13313700% more annual revenue ($66.57B vs $500,000). MRK leads profitability with a 4.8% profit margin vs 0.0%. PALI trades at a lower P/E of 3.2x. MRK earns a higher WallStSmart Score of 36/100 (F).

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

PALI

Avoid

27

out of 100

Grade: F

Growth: 4.3Profit: 2.5Value: 8.3Quality: 7.3
Piotroski: 3/9Altman Z: 14.79
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$143.93

$61.09 premium

UndervaluedFair: $82.84Overvalued
PALIUndervalued (+55.6%)

Margin of Safety

+55.6%

Fair Value

$3.92

Current Price

$2.06

$1.86 discount

UndervaluedFair: $3.92Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

PALI3 strengths · Avg: 9.3/10
P/E RatioValuation
3.2x10/10

Attractively priced relative to earnings

Altman Z-ScoreHealth
14.7910/10

Safe zone — low bankruptcy risk

Price/BookValuation
2.9x8/10

Reasonable price relative to book value

Areas to Watch

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

PALI4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$364.23M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bull Case : PALI

The strongest argument for PALI centers on P/E Ratio, Altman Z-Score, Price/Book.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Bear Case : PALI

The primary concerns for PALI are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

PALI carries more volatility with a beta of 1.55 — expect wider price swings.

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (36/100 vs 27/100). PALI offers better value entry with a 55.6% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Palisade Bio Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Leading BioSciences, Inc. develops therapies to improve human health through therapeutic protection of the gastrointestinal mucosal barrier. The company is headquartered in Carlsbad, California.

Visit Website →

Want to dig deeper into these stocks?